Roche has announced an investment of US $50 billion into the United States of America in the next five years across its pharmaceutical and diagnostics divisions.
As part of this investment, Roche will increase its existing footprint of more than 25,000 employees in 24 sites across eight US states. The investment will include:
- Expanded and upgraded US manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon and California
- A state-of-the-art gene therapy manufacturing facility in Pennsylvania
- A new 900,000 square foot manufacturing centre to support Roche’s expanding portfolio of next generation weight loss medicines (location to be announced)
- A new manufacturing facility for continuous glucose monitoring in Indiana
- A new R&D centre in Massachusetts, conducting cutting-edge artificial intelligence (AI) research and serving as hub for new cardiovascular, renal and metabolism research and development efforts
- Significant expansion and upgrading of existing pharmaceuticals and diagnostics R&D centres in Arizona, Indiana and California.
“Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the US,” said Thomas Schinecker, Roche Group CEO. “We are proud of our 110-year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions. Our investments over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”
Once all new and expanded manufacturing capacity comes on-line, Roche will export more medicines from the US than it imports. Today, its diagnostics division already has an export surplus from the US to other countries.